Cargando…
Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker
Diffuse large B cell lymphoma (DLBCL) is a heterogeneous group of aggressive lymphomas that can be classified into three molecular subtypes by gene expression profiling (GEP): GCB, ABC and unclassified. Immunohistochemistry-based cell of origin (COO) classification, as a surrogate for GEP, using thr...
Autores principales: | Batlle-López, Ana, de Villambrosía, Sonia González, Francisco, Mazorra, Malatxeberria, Sefora, Sáez, Anabel, Montalban, Carlos, Sánchez, Lydia, Garcia, Juan F., González-Barca, Eva, López-Hernández, Andrés, Ruiz-Marcellan, MC, Mollejo, Manuela, Grande, Carlos, Richards, Kristy L., Hsi, Eric D., Tzankov, Alexandar, Visco, Carlo, Xu-Monette, Zijun Y., Cao, Xin, Young, Ken H., Piris, Miguel Ángel, Conde, Eulogio, Montes-Moreno, Santiago |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951269/ https://www.ncbi.nlm.nih.gov/pubmed/26910115 http://dx.doi.org/10.18632/oncotarget.7495 |
Ejemplares similares
-
A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas
por: van der Meeren, L. E., et al.
Publicado: (2019) -
Primary Cutaneous DLBCL Non-GCB Type: Challenges of a Rare Case
por: Sica, Antonello, et al.
Publicado: (2020) -
Comparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma
por: Boltežar, Lučka, et al.
Publicado: (2018) -
Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement
por: Geng, Hongzhi, et al.
Publicado: (2023) -
Sir Alfred Keogh, G.C.B., M.D.: The Director-General of the Army Medical Service
Publicado: (1917)